EVALUATION OF ANTIBODY IMMUNOTHERAPY FOR HCV IN CHIMPANZEES

黑猩猩 HCV 抗体免疫治疗的评估

• 批准号: 8357719
• 负责人: Robert E LANFORD
• 金额: $ 3.66万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357719
• 关键词: Antibodies; Drug Kinetics; Evaluation; Funding; Grant; Hepatitis C virus; Immune; Immunotherapy; Interleukin-10; National Center for Research Resources; Pan Genus; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Source; United States National Institutes of Health; Viremia; base; cost; humanized monoclonal antibodies

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This study was performed as a combination antibody pharmacokinetic (PK) and efficacy study to evaluate an immunotherapy based on the inhibition of IL-10 activity using a humanized monoclonal antibody. The desired effect was to increase the immune responsiveness in three chimpanzees chronically infected with HCV and observe the reduction or elimination of viremia.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 这项研究是作为组合抗体药代动力学（PK）和疗效研究进行的，以根据使用人源化的单克隆抗体对IL-10活性的抑制来评估免疫疗法。所需的效果是增加三只黑猩猩长期感染HCV的免疫反应能力，并观察到病毒血症的降低或消除。